HPV DNA testing in cervical cancer screening - Results from women in a high-risk province of Costa Rica

被引:411
|
作者
Schiffman, M
Herrero, R
Hildesheim, A
Sherman, ME
Bratti, M
Wacholder, S
Alfaro, M
Hutchinson, M
Morales, J
Greenberg, MD
Lorincz, AT
机构
[1] NCI, Interdisciplinary Studies Sect, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA
[2] Int Agcy Res Canc, F-69372 Lyon, France
[3] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[4] Costa Rican Social Secur Adm, San Jose, Costa Rica
[5] Brown Univ, Women & Infants Hosp, Providence, RI USA
[6] Omnia, Blue Bell, PA USA
[7] Digene Corp, Silver Spring, MD USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 283卷 / 01期
关键词
D O I
10.1001/jama.283.1.87
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Human papillomaviruses (HPVs) are known to cause most cervical cancer worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not been determined. Objective To provide comprehensive data on the screening performance of HPV testing for the most common carcinogenic types, at different levels of analytic sensitivity. Design Laboratory analysis conducted during 1993-1995, using 3 cytologic techniques and cervicography, followed by colposcopic examination of women with any abnormal cervical finding, to detect all high-grade intraepithelial lesions and cancer (reference standard of clinically significant disease). The HPV testing was performed subsequently with masking regarding clinical findings. Setting Guanacaste Province, Costa Rica, a region with a high age-adjusted incidence of cervical cancer. Participants Of 11742 randomly selected women, 8554 nonpregnant, sexually active women without hysterectomies underwent initial HPV DNA testing using the original Hybrid Capture Tube test; a stratified subsample of 1119 specimens was retested using the more analytically sensitive second generation assay, the Hybrid Capture II test. Main Outcome Measures Receiver operating characteristic analysis of detection of cervical high-grade intraepithelial lesions and cancer by HPV DNA testing based on different cut points of positivity. Results An analytic sensitivity of 1.0 pg/mL using the second generation assay would have permitted detection of 88.4% of 138 high-grade lesions and cancers (all 12 cancers were HPV-positive), with colposcopic referral of 12.3% of women. Papanicolaou testing using atypical squamous cells of undetermined significance as a cut point for referral resulted in 77.7% sensitivity and 94.2% specificity, with 6.9% referred. Specificity of the second generation assay for positivity for high-grade lesions and cancer was 89.0%, with 33.8% of remaining HPV DNA-positive subjects having low-grade or equivocal microscopically evident lesions. The higher detection threshold of 10 pg/mL used with the original assay had a sensitivity of 74.8% and a specificity of 93.4%, Lower levels of detection with the second generation assay (<1 pg/mL) proved clinically nonspecific without gains in diagnostic sensitivity, Conclusions In this study population, a cut point of 1.0 pg/mL using the second generation assay permitted sensitive detection of cervical high-grade lesions and cancer, yielding an apparently optimal trade-off between high sensitivity and reasonable specificity for this test. The test will perform best in settings in which sensitive detection of high-grade lesions and cancer is paramount. Because HPV prevalence varies by population, HPV testing positive predictive value for detection of high-grade lesions and cancer will vary accordingly, with implications for utility relative to other cervical cancer screening methods.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [31] HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
    Kares, Saara
    Veijalainen, Olga
    Kholova, Ivana
    Tirkkonen, Mika
    Vuento, Risto
    Huhtala, Heini
    Tuimala, Veronica
    Maenpaa, Johanna
    Kujala, Paula
    APMIS, 2019, 127 (11) : 710 - 716
  • [32] Prevalence and Determinants of High-risk HPV Infection among 11549 Women from an Opportunistic Screening in Hubei Province
    Quan-fu Ma
    Yu-lin Guo
    Han Gao
    Bin Yan
    Xuan Dai
    Meng Xu
    Yu-jing Xiong
    Qiu-zi Peng
    Ying Wang
    Miao Zou
    Xu-feng Wu
    Current Medical Science, 2019, 39 : 622 - 630
  • [33] Prevalence and Determinants of High-risk HPV Infection among 11549 Women from an Opportunistic Screening in Hubei Province
    Ma, Quan-fu
    Guo, Yu-lin
    Gao, Han
    Yan, Bin
    Dai, Xuan
    Xu, Meng
    Xiong, Yu-jing
    Peng, Qiu-zi
    Wang, Ying
    Zou, Miao
    Wu, Xu-feng
    CURRENT MEDICAL SCIENCE, 2019, 39 (04) : 622 - 630
  • [34] High-Risk HPV Screening Initiative in Kosovo-A Way to Optimize HPV Vaccination for Cervical Cancer
    Bentz, Jessica L.
    Barney, Rachael E.
    Georgantzoglou, Natalia
    Manxhuka-Kerliu, Suzana
    Ibishi, Vlora Ademi
    Dacaj-Elshani, Brikene
    Bejarano, Suyapa
    Palumbo, Paul E.
    Suresh, Arvind
    LaRochelle, Ethan P. M.
    Keegan, William P.
    Wilson, Teresa L.
    Dokus, Betty J.
    Hershberger, Kenneth C.
    Gallagher, Torrey L.
    Allen, Samantha F.
    Palisoul, Scott M.
    Steinmetz, Heather B.
    Kennedy, Linda S.
    Tsongalis, Gregory J.
    DISEASES, 2024, 12 (08)
  • [35] Validation of high-risk HPV tests for primary cervical screening
    Meijer, C. J. L. M.
    Berkhof, H.
    Heideman, D. A. M.
    Hesselink, A. T.
    Snijders, P. J. F.
    JOURNAL OF CLINICAL VIROLOGY, 2009, 46 : S1 - S4
  • [36] HPV Testing for Cervical Cancer in Romania: High-Risk HPV Prevalence among Ethnic Subpopulations and Regions
    Ilisiu, Minodora Bianca
    Hashim, Dana
    Andreassen, Trude
    Stoer, Nathalie C.
    Nicula, Florian
    Weiderpass, Elisabete
    ANNALS OF GLOBAL HEALTH, 2019, 85 (01):
  • [37] Outcomes of HPV positive results in women following primary cervical cancer screening with HPV DNA test in Singapore
    Lim, L. M.
    Low, J. J. H.
    Ng, J. S. Y.
    Ilancheran, A.
    Koay, E.
    Yu, E. D.
    Ismail, I. S.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 125 : 123 - 123
  • [38] SCREEN-AND-TREAT CERVICAL CANCER SCREENING STRATEGY USING HIGH-RISK HPV TESTING: EARLY EVALUATION FOR UGANDA
    Sultanov, M.
    van der Schans, J.
    Koot, J. A. R.
    de Zeeuw, J.
    Nakisige, C.
    Greuter, M. J. W.
    Greuter, J. J.
    de Fouw, M.
    Stekelenburg, J.
    de Bock, G. H.
    VALUE IN HEALTH, 2023, 26 (12) : S186 - S186
  • [39] Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening
    Naucler, Pontus
    Ryd, Walter
    Tornberg, Sven
    Strand, Anders
    Wadell, Goran
    Elfgren, Kristina
    Radberg, Thomas
    Strander, Bjorn
    Forslund, Ola
    Hansson, Bengt-Goran
    Hagmar, Bjorn
    Johansson, Bo
    Rylander, Eva
    Dillner, Joakim
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (02): : 88 - 99
  • [40] High frequency of HPV high-risk preventable genotypes in Ecuadorian women with invasive cervical cancer
    Muentes, Gustavo David Garcia
    Latif, Fadi Abdul
    Rodriguez, Claudia Catalina Beltran
    Gonzalez, Sebastian Medina
    Cabezas, Juan Carlos Ruiz
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2024, 48